On the stock market since 2016, it operates in the world of health and science. It has 2,400 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 32% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 22% a year on average.
The company sells $747.1M a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $176 — 37% above today’s price.
A loss of $44.6M against $747.1M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 14/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 36/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, IRTC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IRTC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.